Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | BHMT | Q93088 | 1/20 | 0.30 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29105339 | 0.98 | ACE2 (0.31) | ACE2 | |
| Hydrochloric Acid SCHEMBL9488746 | 0.98 | ACE2 (0.31) | ACE2 | |
| SCHEMBL31499508 | 0.98 | ACE2 (0.31) | ACE2 | |
| SCHEMBL3775674 | 0.90 | ACACB (0.32) | — | |
| SCHEMBL27691369 | 0.85 | ACE2 (0.33) | ACE2 | |
| SCHEMBL24201161 | 0.85 | — | — | |
| SCHEMBL28723120 | 0.84 | ACE (0.31) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9173986 | 0.83 | — | — | |
| SCHEMBL23170345 | 0.83 | — | — | |
| SCHEMBL24201038 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026044024-A1 | COMPOSITIONS COMPRISING COMBINATIONS OF PHARMACEUTICALLY ACCEPTABLE SALTS AND OTHER DERIVATIVES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND PHARMACEUTICALLY ACCEPTABLE SALTS AND OTHER DERIVATIVES OF AMYLIN ANALOG, AND USES THEREOF | I2O THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| EP-4429704-A1 | IONIC LIQUID COMPOSITIONS | I2O Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| US-20240130994-A1 | IONIC LIQUID FORMULATIONS FOR TREATING DIABETES | I2O THERAPEUTICS, INC. | 2024-04-25 | — | — | US | claimed |
| WO-2023086499-A1 | IONIC LIQUID COMPOSITIONS | I2O THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| WO-2023037976-A1 | LIQUID OILY COMPOSITION AND COSMETIC CONTAINING SAME | 日清オイリオグループ株式会社 | 2023-03-16 | — | — | WO | claimed |
| CN-113603431-B | Preparation method of waterproof toughened sandy soil consolidation agent | 黄河勘测规划设计研究院有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-113603431-A | Preparation method of waterproof toughened sandy soil consolidation agent | 黄河勘测规划设计研究院有限公司 | 2021-11-05 | — | — | CN | claimed |
| CN-112262122-A | Compound or salt thereof, and lipid particle | 富士胶片株式会社 | 2021-01-22 | — | — | CN | claimed |
| EP-1782789-B1 | LIQUID ESTER COMPOSITION AND COSMETIC PREPARATION CONTAINING THE SAME | NISSHIN OILLIO GROUP LTD (JP) | 2016-11-30 | — | — | EP | claimed |
| CN-105524489-A | In-situ emulsification modification method for nano calcium carbonate for polyurethane sealant | ZHEJIANG TIANSHI NANO-TECH CO LTD | 2016-04-27 | — | — | CN | claimed |
| WO-2007089835-A2 | IMPROVED HIGH TEMPERATURE LUBRICANT COMPOSITIONS | INOLEX INVESTMENT CORP. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20070179069-A1 | High temperature lubricant compositions | INOLEX INVESTMENT CORPORATION (US) | 2007-08-02 | — | — | US | claimed |
| US-20070110702-A1 | Liquid ester compositions and cosmetic compositions containing the same | THE NISSHIN OILLIO GROUP, LTD. (JP) | 2007-05-17 | — | — | US | claimed |
| EP-1782789-A1 | LIQUID ESTER COMPOSITION AND COSMETIC PREPARATION CONTAINING THE SAME | The Nisshin Oillio Group, Ltd. (JP) | 2007-05-09 | — | — | EP | claimed |
| US-5461170-A | Diglyceride from branched and straight chain fatty acids | KAO CORPORATION (JP) | 1995-10-24 | — | — | US | claimed |
| EP-0658629-A1 | Process for preparation of polyol fatty acid ester and glyceride mixture obtained | Kao Corporation (JP) | 1995-06-21 | — | — | EP | claimed |
| US-5080889-A | Oil, oxidation resistance, stability | KAO CORPORATION (JP) | 1992-01-14 | — | — | US | claimed |
| EP-0391431-A1 | Diacylglycerin and cosmetic composition | KAO CORPORATION (JP) | 1990-10-10 | — | — | EP | claimed |
| EP-0319126-A2 | Process for preparation of polyol fatty acid ester and glyceride mixture obtained | Kao Corporation (JP) | 1989-06-07 | — | — | EP | claimed |
| EP-0028456-B1 | BRANCHED FATTY ACID CHOLESTEROL ESTER AND A COSMETIC COMPOSITION CONTAINING THE SAME | Kao Corporation (JP) | 1983-03-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240130994-A1 | IONIC LIQUID FORMULATIONS FOR TREATING DIABETES | GPR119, FABP4, PNLIP | ACE2 2974/4885SLC1A3 342/4885SLC1A2 449/4885 |
| US-20070110702-A1 | Liquid ester compositions and cosmetic compositions containing the same | MITF, DEK, EBP | ACE2 4849/4885SLC1A3 4652/4885SLC1A2 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.